Evidence map›Paper›PMID 38376151›Full record

ArticleMicrobiology spectrum2024

Investigating inhibitors of 1-deoxy-d-xylulose 5-phosphate synthase in a mouse model of UTI.

Eric C Chen, Rachel L Shapiro, Arindom Pal, David Bartee, Kevin DeLong, Davell M Carter, Erika Serrano-Diaz, Rana Rais, Laura M Ensign, Caren L Freel Meyers

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Eric C ChenDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-2799-3885
Rachel L ShapiroCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Arindom PalDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
David BarteeDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Kevin DeLongCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Davell M CarterDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Erika Serrano-DiazDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Rana RaisDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Laura M EnsignDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Caren L Freel MeyersDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins University · US

Funding

PHARMACOLOGY TRAINING GRANTT32GM008763 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI FREEL MEYERS, CAREN L. · 2000 to 2019
$6.1M
Nanomedicine approaches for prevention of inflammation-induced preterm birthR01HD103124 · NICHD · JOHNS HOPKINS UNIVERSITY · PI BURD, IRINA, ENSIGN, LAURA · 2021 to 2025
$3.3M
Pharmacology and Molecular Sciences Training Program: Enhancing Inclusivity Through Universal Design for Learning in Graduate CoursesT32GM135083 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Caren L. Freel Meyers · 2020 to 2026
$3.3M
Targeting Non-mammalian Isoprenoid BiosynthesisR01GM084998 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI FREEL MEYERS, CAREN L. · 2010 to 2019
$3.0M
Targeting DXP synthase in bacterial metabolismR01AI161020 · NIAID · JOHNS HOPKINS UNIVERSITY · PI FREEL MEYERS, CAREN L. · 2021 to 2025
$2.7M
Toward targeting bacterial metabolism: Relevance, mechanism and function of DXP synthaseR56AI150221 · NIAID · JOHNS HOPKINS UNIVERSITY · PI FREEL MEYERS, CAREN L. · 2020 to 2020
$640k
NIAID NIH HHS R01 AI161020NIAID NIH HHS R56 AI150221NICHD NIH HHS R01 HD103124NIGMS NIH HHS R01 GM084998NIGMS NIH HHS T32 GM008763NIGMS NIH HHS T32 GM135083
6 · The paper itself

Abstract

The rising rate of antimicrobial resistance continues to threaten global public health. Further hastening antimicrobial resistance is the lack of new antibiotics against new targets. The bacterial enzyme, 1-deoxy-d-xylulose 5-phosphate synthase (DXPS), is thought to play important roles in central metabolism, including processes required for pathogen adaptation to fluctuating host environments. Thus, impairing DXPS function represents a possible new antibacterial strategy. We previously investigated a DXPS-dependent metabolic adaptation as a potential target in uropathogenic

Indexed as

Anti-Infective AgentsEscherichia coli InfectionsPentosephosphatesProdrugsUrinary Tract InfectionsUropathogenic Escherichia coliAcetaldehydeAnimalsAnti-Bacterial AgentsMice1-deoxylulose 5-phosphateAcetaldehydeAnti-Bacterial AgentsAnti-Infective AgentsPentosephosphatesphosphonoacetaldehydeProdrugs1-deoxy-d-xylulose 5-phosphate synthaseacetylphosphonateantibioticcentral metabolismDXPSMEPUTI

Identifiers

PMID38376151
PMCPMC10986598
OpenAlexW4391955707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.